Physician profile
Mark Ayoub
NPI 1689961310
$414,852.74
in general payments reported to CMS, 2019-2025
6 companies · $78K in 2025
The $78K reported for 2025 was more than what 96% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $5,014 · 2021: $83K · 2022: $85K · 2023: $89K · 2024: $75K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $240K · Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $240,392.00 |
| Food and Beverage | $971.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Central California Surgical Distributors, LLC | $413,639.00 | 2020-2025 | |
| Depuy Synthes Sales INC. | $533.68 | 2022-2024 | Na, Motoband |
| Stryker Corporation | $361.78 | 2019-2025 | Gamma, Axsos, Variax |
| Smith+Nephew, INC. | $270.24 | 2019-2025 | Evos, Pico 14 |
| Cornerstone Medical Associates, INC. | $25.29 | 2023 | |
| Kci USA, INC. | $22.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$309,362.14 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ayoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.